Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Sci Rep ; 14(1): 13995, 2024 Jun 18.
Artículo en Inglés | MEDLINE | ID: mdl-38886477

RESUMEN

As mechanized open-pit coal mining intensifies, assessing and predicting slope stability has become increasingly important. To address the limitations of traditional mechanical calculations, numerical simulations, and physical experiments, this paper identifies the key factors impacting slope stability in open-pit mines and develops a multi-parameter sample data set. The study employs hyperparameters optimized using a Bayesian algorithm, introduces additional convolutional layers, and combines the Adam optimizer with dropout techniques to enhance the feature extraction and performance of one-dimensional convolutional neural networks (1D-CNN). This leads to a Bayesian-optimized one-dimensional convolutional neural network (B-1D MCNN) model for predicting slope stability.The study evaluates the classification performance and accuracy of various models for slope stability, including BP neural networks, genetic algorithm-optimized convolutional neural networks, 1D-CNN, and B-1D MCNN, using accuracy, precision, and F1-score as metrics. The analysis also examines the influence of factor indicators and training set length on the model's output to assess its generalization capabilities.The research findings suggest that: (1) the B-1D MCNN model for evaluating slope stability demonstrates the capability to accurately depict the nonlinear correlation between influencing factors and slope stability. (2) Compared with other models, the B-1D MCNN model has shown enhancements of 10.96% to 27.85%, 10.26% to 28.55%, and 8.98% to 25.05% in terms of Accuracy, F1-Score, and Precision, respectively. (3) As the length of the training dataset increases, the performance of the model improves accordingly. (4) The B-1D MCNN model shows a generalization power of 87.5%.

2.
Zhonghua Gan Zang Bing Za Zhi ; 17(3): 171-4, 2009 Mar.
Artículo en Chino | MEDLINE | ID: mdl-19335977

RESUMEN

OBJECTIVE: To explore the strategy for the treatment of chronic hepatitis B with YMDD mutation. METHODS: A total of 120 chronic hepatitis B patients with YMDD mutation were randomly assigned into four groups. In group A, patients received adefovir dipivoxil for 48 weeks. In group B, patients received adefovir dipivoxil in combination with lamivudine during the first 12 weeks and adefovir dipivoxil only for the following 36 weeks. In group C, patients received adefovir dipivoxil in combination with lamivudine for 48 weeks. In group D, patients received entecavir for 48 weeks. RESULTS: The rate of rebound of alanine aminotransferase (ALT) was 30.0% (9/30), 10.0% (3/30), 6.7% (2/30), 10.0% (3/30) (P < 0.05) during the first 12 weeks, and one patient with severe hepatitis was found in group A. The positive rate of YMDD mutation was 17.9%, 0, 0, 0 at week 12. There was no significant difference in the level of ALT and the rate of HBeAg seroconversion after 48-week treatment (P > 0.05). At week 48, there was significant difference in the ALT normalization rate and undetectable HBV DNA rate between group C and group A, and also between group D and group A, and the rate of drug resistant genotype was 6.9%, 6.7%, 0, 0. Two patients had rtN236T mutation in group A, and one patient had rtN236T mutation and another one had rtA181V mutation in group B. CONCLUSION: Adefovir dipivoxil in combination with lamivudine or entecavir are safe and effective therapies for chronic hepatitis B patients with YMDD mutation.


Asunto(s)
Antivirales/uso terapéutico , ADN Viral/sangre , Virus de la Hepatitis B/genética , Hepatitis B Crónica/tratamiento farmacológico , Hepatitis B Crónica/virología , Adenina/administración & dosificación , Adenina/análogos & derivados , Adenina/uso terapéutico , Adulto , Alanina Transaminasa/sangre , Antivirales/administración & dosificación , Farmacorresistencia Viral , Quimioterapia Combinada/métodos , Femenino , Estudios de Seguimiento , Guanina/administración & dosificación , Guanina/análogos & derivados , Guanina/uso terapéutico , Antígenos e de la Hepatitis B/sangre , Virus de la Hepatitis B/efectos de los fármacos , Humanos , Lamivudine/administración & dosificación , Lamivudine/uso terapéutico , Masculino , Persona de Mediana Edad , Mutación , Organofosfonatos/administración & dosificación , Organofosfonatos/uso terapéutico , Inhibidores de la Transcriptasa Inversa/administración & dosificación , Inhibidores de la Transcriptasa Inversa/uso terapéutico , Adulto Joven
3.
Zhonghua Gan Zang Bing Za Zhi ; 16(10): 748-51, 2008 Oct.
Artículo en Chino | MEDLINE | ID: mdl-18983771

RESUMEN

OBJECTIVE: To explore the influence of beta-elemene on the proliferation, migration and RhoA expression of hepatic stellate cells (HSC) induced by angiotensin II (ANG II). METHODS: HSC were incubated in vitro. Proliferation and migration of the HSC were induced by ANG II. The effect on the proliferation of HSC was determined by MTT colorimetry. The migration ability was detected by transwell chamber cultures. Total RNA was extracted by TRizol reagent and gene levels were determined by semi-quantitative RT-PCR. Protein levels were determined by Western blot. RESULTS: Different concentrations (from 1 to 10 micromol/L) of ANG II markedly promoted the growth of the HSC in a concentration dependent way (0 micromol/L ANG II, F = 112.640, P less than 0.01). 10, 8, 4 micromol/L ANGII significantly induced HSC migration, F = 117.496, P less than 0.01. Compared with the 4 micromol/L ANG II group, 10 mg/L, 5 mg/L, 2.5 mg/L beta-elemene markedly inhibited HSC proliferation and migration induced by 4 micromol/L ANG II (F values were 95.706 and 55.600 and P less than 0.01). 4 micromol/L ANG II markedly promoted the protein and mRNA expressions of RhoA in HSC. 10 mg/L, 5 mg/L and 2.5 mg/L beta-elemene notably inhibited the expressions of RhoA protein and mRNA (F values were 217.119 and 18.010). CONCLUSION: ANG II can significantly induce the proliferation and migration of HSC. Beta-elemene can inhibit the proliferation and migration of HSC induced by ANG II. The effects of beta-elemene are mediated through inhibiting the RhoA signal transduction pathway and are associated with RhoA.


Asunto(s)
Movimiento Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Células Estrelladas Hepáticas/efectos de los fármacos , Sesquiterpenos/farmacología , Proteína de Unión al GTP rhoA/metabolismo , Angiotensina II/farmacología , Células Cultivadas , Células Estrelladas Hepáticas/citología , Humanos
5.
Zhonghua Yi Xue Yi Chuan Xue Za Zhi ; 20(1): 66-8, 2003 Feb.
Artículo en Chino | MEDLINE | ID: mdl-12579507

RESUMEN

OBJECTIVE: To investigate the relationship between carotid artery intima media thickness (IMT) and apolipoprotein (Apo) E gene polymorphisms in type 2 diabetes mellitus (DM2). METHODS: Two hundred and fifty-five DM2 patients without angiopathy and 107 healthy individuals were selected. PCR/allele-specific oligonucleotide probe was used to determine their apoE genotypes. RESULTS: The prevalence distribution of apoE genotypes and alleles in DM2 patients and that in controls were similar. The TC, LDL-C and Lp(a) concentrations in e4/4, e4/3 subgroups were significantly higher than those in e3/2, e2/2 subgroups (P<0.05). The average value of IMT in e4/4 e4/3 carriers (0.89 mm) was significantly greater than that in e3/2 e2/2 carriers (0.62 mm) (P<0.05). After adjustment for TC, LDL-C, TG, Lp(a), FBG, HbA1c, age, BMI, and smoking, ANCOVA showed that the average value of carotid IMT was significantly greater in subjects with e4/4 e4/3, compared with that in subjects with e3/2 e2/2(P=0.033). CONCLUSION: Apo e4 allele increases the risk for carotid artery atherosclerosis in the early stage of diabetic population.


Asunto(s)
Apolipoproteínas E/genética , Arteriosclerosis/patología , Enfermedades de las Arterias Carótidas/patología , Diabetes Mellitus Tipo 2/genética , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Alelos , Análisis de Varianza , Apolipoproteína E4 , Índice de Masa Corporal , Colesterol/sangre , LDL-Colesterol/sangre , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/patología , Femenino , Frecuencia de los Genes , Genotipo , Hemoglobina Glucada/metabolismo , Humanos , Lipoproteína(a)/sangre , Masculino , Persona de Mediana Edad , Fumar , Triglicéridos/sangre , Túnica Íntima/patología , Túnica Media/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...